Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCTO
Special Issues
Retinal Diseases: Recent Advances in Diagnosis and Treatment
share announcement

Retinal Diseases: Recent Advances in Diagnosis and Treatment

A special issue of Journal of Clinical & Translational Ophthalmology (ISSN 2813-1053).

Deadline for manuscript submissions: closed (15 June 2025) | Viewed by 1278

Special Issue Editors

Dr. Dario Giorgio

E-Mail Website
Guest Editor
1. Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
2. Ophthalmology Unit, Riuniti Hospital, Azienda Ospedaliera Toscana Nord Ovest Viale Vittorio Alfieri 36, 57124 Livorno, Italy
Interests: retinal diseases; retinal pigment epithelium; inherited retinal degeneration; gene therapy for inherited diseases; imaging biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Dario Pasquale Mucciolo

E-Mail
Guest Editor
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Ophthalmology Unit, San Jacopo Hospital, Via Ciliegiole 97, 51100 Pistoia, Italy
Interests: retinal diseases; ophthalmology; retinal degeneration; macular degeneration clinical ophthalmology; OCT; retinal imaging; optical coherence tomography; fluorescein angiography
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, we have witnessed significant advances in the diagnosis and treatment of retinal diseases. These advances have been made possible by the development of novel imaging technologies, such as optical coherence tomography (OCT) and angiography, which enable the detailed visualization of the retina. In addition, there have been major advances in the development of novel drugs and gene therapies for retinal diseases.

Some of the recent advances in the diagnosis and treatment of retinal diseases include the following:

  • The development of new imaging technologies, such as OCT and angiography, which enable the detailed visualization of the retina.
  • The development of new drugs, such as anti-vascular endothelial growth factor (VEGF) drugs, which can be employed to treat wet age-related macular degeneration (AMD).
  • The development of gene therapies, such as Luxturna®, which can be used to treat inherited retinal diseases.

These advances have led to improved outcomes for patients with retinal diseases. However, there is still much to be achieved in the field. This Special Issue in the Journal of Clinical & Translational Ophthalmology, focusing on retinal diseases, will connect leading experts in the field to discuss the latest advances in this area. The articles in this Special Issue will provide valuable insights into the potential of these advances to improve the diagnosis and treatment of retinal diseases.

You may choose our Joint Special Issue in JCM.

Dr. Dario Giorgio
Dr. Dario Pasquale Mucciolo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical & Translational Ophthalmology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal diseases
  • retinal degeneration
  • macular degeneration
  • OCT
  • retinal imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 807 KB  
Review
Racial and Gender Disparities in Clinical Trial Representation for Age-Related Macular Degeneration Treatments: A Scoping Review
by Amirmohammad Shafiee, Taylor Juran, Iza Zabaneh, Deepkumar Patel and Karen Allison
J. Clin. Transl. Ophthalmol. 2025, 3(3), 16; https://doi.org/10.3390/jcto3030016 - 13 Aug 2025
Viewed by 279
Abstract
Background/Objective: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the primary treatment for neovascular AMD. This study aimed to assess racial, ethnic, and gender representation in U.S.-based randomized controlled trials (RCTs) [...] Read more.
Background/Objective: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the primary treatment for neovascular AMD. This study aimed to assess racial, ethnic, and gender representation in U.S.-based randomized controlled trials (RCTs) of anti-VEGF therapies. Methods: A systematic PubMed search identified 19 eligible RCTs. Titles and abstracts were screened, and demographic data were independently extracted and cross-verified. Chi-squared analysis was used to evaluate disparities in participant representation. Risk of bias was assessed using the ROBIS checklist. Results: Among 8003 participants across 19 trials, 92.3% were Caucasian. Asian, African American, Hispanic/Latino, and American Indian participants collectively comprised just over 5%. This underrepresentation of non-Caucasian groups was statistically significant (p < 0.01, df = 4) and not associated with study sponsorship. Gender analysis showed 59% female and 41% male participation, which was not statistically significant (p = 0.83, df = 1). Conclusions: Non-Caucasian populations remain significantly underrepresented in anti-VEGF RCTs for AMD. This raises concerns about the generalizability of trial findings to diverse populations. Future clinical trials must prioritize inclusive recruitment to ensure equitable, evidence-based care for all patients. Full article
(This article belongs to the Special Issue Retinal Diseases: Recent Advances in Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop